Subscribe to RSS - ASP

ASP

OIG recommends CMS review Part B drug prices

 - 
05/16/2019

WASHINGTON – The average sales price for 10 drug codes for the fourth quarter of 2018 exceeded the average manufacture price by 5% or more for two consecutive quarters, according to a new report from the Of

NHIA responds to OIG report on infusion payments

 - 
09/16/2016

ALEXANDRIA, Va. – A recent Office of Inspector General report on payment for Part B DME infusion drugs is far too narrow to be the basis for new policy, according to the National Home Infusion Association.

ASP rises for several drugs

 - 
09/23/2015

BALTIMORE – Fourth-quarter payments showed healthy increases for several respiratory drugs. Brand name drugs Brovana (J7605) rose 88 cents to $8.08 per dose and Perforomist (J7606) rose 40 cents to $8.88 per dose.

OIG: CMS overpays for infusion drugs

 - 
04/23/2015

WASHINGTON – CMS could have saved $251 million over an 18-month period if it paid for DME infusion drugs using an average sales price methodology, according to a new report from the Office of Inspector General.

ASP: Budesonide back down

 - 
04/26/2013

BALTIMORE – Pricing for budesonide took a plunge in the latest average sales price (ASP) figures for respiratory medications released in March.

In brief: ResMed lawsuit, surety bond update

 - 
03/29/2013

SAN DIEGO – ResMed has sued Taiwanese manufacturer Apex Medical and its U.S. distributor, Medical Depot, doing business as Drive Medical, to stop alleged patent infringement. ResMed has filed parallel legal actions in the International Trade Commission (ITC) and U.S.